[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"peyronies-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:peyronies-disease":82},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100606613","phase-1-title-fractioned-co2-laser-in-the-treatment-of-chronic-phase-peyronies-disease-100606613",false,"NCT07177833","Title Fractioned CO2 Laser in the Treatment of Chronic Phase Peyronie's Disease","Inclusion Criteria:\n\n1. Men 18 or older. For heterosexual men it is required they be in a stable relationship with a female spouse\u002Fpartner for at least 3 months and willing to have vaginal intercourse for purposes of properly filling out the validated PD Questionnaire.\n2. Diagnosis of PD for at least 12 months with evidence of stable disease as determined by the investigator (i.e. no change in penile curve for at least 6 months and absence of pain).\n3. Penile curvature of 30º-90º in the dorsal, lateral, or dorsal\u002Flateral plane (must be possible to delineate the single plane of maximal curvature for evaluation)\n4. Signed informed REB-approved consent agreement; signed authorization form to allow disclosure of protected information.\n5. Ability to read, complete, and understand the various rating instruments in English.\n\nExclusion Criteria:\n\n1. Penile curvature of \\\u003C30º or \\>90º\n2. Any conditions affecting the penis such as a chordee in the presence or absence of hypospadias; thrombosis of the dorsal penile artery; infiltration by a benign or malignant mass or an infectious agent; ventral curvature from any cause; presence of an active sexually transmitted disease.\n3. Failure to achieve a sufficient 8\u002F10 erection (after prostaglandin E or Trimix administration), in the opinion of the investigator, to accurately measure the penile deformity.\n4. Calcified plaque as evident by appropriate radiographic evaluation, i.e., penile ultrasound that would prevent treatment with Fractional CO2 Laser\n5. Isolated hourglass deformity of the penis without curvature\n6. Treatment or plans to undergo treatment for PD, including but not limited to any previous surgery, oral\u002Ftopical agents within 3 months, intralesional medical therapies within 3 months, extracorporeal shock wave therapy within 6 months, or use of mechanical devices within 2 weeks before the start of the study","MALE","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE1","Peyronie's Disease (PD) is a fibrosing disorder of the penis where scar tissue (composed of excessive and disorganized collagen) known as a \"plaque,\" forms along the shaft of the penis. This plaque can lead to permanent penile deformity (curvature, narrowing, indentation, hinging), loss of penile length, erectile dysfunction, and pain during intercourse. Research has shown PD to negatively impact the quality of life and cause significant psychosocial distress for many men.\n\nAt present, available medical and surgical treatment modalities for PD have limitations. Intralesional collagenase clostridium histolyticum (CCh) is approved for the reduction of penile curvature in PD, however, its use is restricted to the United States market. Other medical therapies including intralesional verapamil and interferon injections have inconsistent and modest effects while, invasive surgical management with plication or grafting can result in erectile dysfunction, penile length shortening, penile sensory changes, and harvest site complications.\n\nFractional CO2 Laser Therapy is an extra-dermal (applied to the surface of the skin) and non-invasive treatment that involves the use of lasers to destroy and reduce abnormal collagen in scarred tissue. Most recently, it has been used in a pilot clinical trial investigating its use in the management of PD. All men in this study safely experienced reduction in their penile curvature.\n\nThis will be a phase 1 clinical trial evaluating the safety and feasibility of using a fractional CO2 laser in the management of chronic phase PD. Enrolled study participants will undergo an initial clinical assessment of their PD which involves penile measurements at flaccid and erect states, a curvature assessment with duplex ultrasound, and will be asked to complete the International Index of Erectile Function Questionnaire (IIEF-5), and Peyronie's Disease Questionnaire (PDQ). They will then undergo 3 laser therapy sessions at 6 week intervals and will have a short and long-term follow-up of 24 and 52 weeks, respectively.",[25],"Peyronies Disease",[27],"Peyronies disease","RECRUITING","2025-09-10",{"date":31,"type":32},"2025-09-17","ACTUAL",{"date":34,"type":19},"2025-10-01",{"date":36,"type":19},"2027-10-01",{"name":38,"class":39},"Ottawa Hospital Research Institute","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":20,"phases":50,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":40},"100602011","platelet-rich-plasma-for-peyronies-disease-100602011","NCT07117955","Platelet-Rich Plasma for Peyronie's Disease","Treatment of Peyronie's Disease With Platelet-Rich Plasma: A Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n* 18 years or older\n* Be able to provide written informed consent\n* Diagnosis of PD without active pain and without progressive curvature over the past 3 months (fibrotic phase).\n* Penile curvature of 30-95 degrees\n* Clearly palpable penile plaque\n\nExclusion Criteria:\n\n* Erectile Dysfunction unresponsive to on-demand PDE5 inhibitors\n* Hourglass malformation\n* Severely calcified plaques where injection is considered unfeasible\n* Intrapenile plaque\n* History of priapism.\n* History of penile fracture.\n* Previous treatment for PD with injections and\u002For surgery.\n* Antithrombotic therapy associated with a high risk of bleeding",{"count":49,"type":19},84,[51],"NA","The purpose of this clinical trial is to evaluate the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase.",[25],[55,56,57,58],"Andrology","Platelet-Rich Plasma","Penile induration","PRP","2025-08-11",{"date":61,"type":32},"2025-08-14",{"date":63,"type":19},"2025-09-20",{"date":65,"type":19},"2028-09-01",{"name":67,"class":39},"Herlev Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":75,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":78,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":40},"100450614","phase-1-safety-of-cultured-allogeneic-adult-umbilical-cord-stem-cells-for-peyronies-disease-ed-and-interstitial-cystitis-100450614","NCT05147779","Safety of Cultured Allogeneic Adult Umbilical Cord Stem Cells for Peyronie's Disease, ED, and Interstitial Cystitis","Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis","Inclusion Criteria:\n\n* Diagnosis of Peyronie's Disease, erectile dysfunction, or Interstitial Cystitis\n* Understanding and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* Active infection\n* Active cancer\n* Chronic multisystem organ failure\n* Pregnancy\n* Clinically significant Abnormalities on pre-treatment laboratory evaluation\n* Medical condition that would (based on the opinion of the investigator) compromise patient's safety.\n* Continued drug abuse\n* Pre-menopausal women not using contraception\n* Previous organ transplant\n* Hypersensitivity to sulfur","ALL",{"count":77,"type":19},20,[22],"This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis",[81,82,83],"Erectile Dysfunction","Peyronie's Disease","Interstitial Cystitis",[81,82,85,83],"stem cell treatment","2025-04-15",{"date":88,"type":32},"2025-04-17",{"date":90,"type":32},"2021-09-12",{"date":92,"type":19},"2025-12",{"name":94,"class":39},"The Foundation for Orthopaedics and Regenerative Medicine"]